Details of the Drug

General Information of Drug (ID: DM4LTKV)

Drug Name
Dalfopristin
Synonyms 5-(2-DIETHYLAMINO-ETHANESULFONYL)-21-HYDROXY-10-ISOPROPYL-11,19-DIMETHYL-9,26-DIOXA-3,15,28-TRIAZA-TRICYCLO[23.2.1.00,255]OCTACOSA-1(27),12,17,19,25(28)-PENTAENE-2,8,14,23-TETRAONE
Indication
Disease Entry ICD 11 Status REF
Bacterial infection 1A00-1C4Z Approved [1]
Therapeutic Class
Antibiotics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 2 Molecular Weight (mw) 690.8
Topological Polar Surface Area (xlogp) 2.2
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 11
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 16 mL/min/kg [3]
Elimination
4.5% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.70 hours [3]
Metabolism
The drug is metabolized via the hydrolysis [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 15.198 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.82% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.39 L/kg [3]
Chemical Identifiers
Formula
C34H50N4O9S
IUPAC Name
(6R,7S,10R,11R,12E,17E,19E,21S)-6-[2-(diethylamino)ethylsulfonyl]-21-hydroxy-11,19-dimethyl-10-propan-2-yl-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.03,7]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone
Canonical SMILES
CCN(CC)CCS(=O)(=O)[C@@H]1CCN2[C@H]1C(=O)O[C@@H]([C@@H](/C=C/C(=O)NC/C=C/C(=C/[C@H](CC(=O)CC3=NC(=CO3)C2=O)O)/C)C)C(C)C
InChI
InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9+,12-11+,23-18+/t24-,25-,28-,31-,32-/m1/s1
InChIKey
SUYRLXYYZQTJHF-VMBLUXKRSA-N
Cross-matching ID
PubChem CID
6323289
ChEBI ID
CHEBI:4309
CAS Number
112362-50-2
DrugBank ID
DB01764
TTD ID
D05AFC

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial 50S ribosomal RNA (Bact 50S rRNA) TTUWYEA NOUNIPROTAC Binder [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dalfopristin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Troleandomycin DMUZNIG Moderate Decreased metabolism of Dalfopristin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [16]
Coadministration of a Drug Treating the Disease Different from Dalfopristin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Decreased metabolism of Dalfopristin caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [17]
Midostaurin DMI6E0R Moderate Decreased metabolism of Dalfopristin caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [18]
Gilteritinib DMWQ4MZ Moderate Decreased metabolism of Dalfopristin caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [19]
Oliceridine DM6MDCF Major Decreased metabolism of Dalfopristin caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [20]
Ivabradine DM0L594 Major Decreased metabolism of Dalfopristin caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [19]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Dalfopristin caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [21]
Cariprazine DMJYDVK Moderate Decreased metabolism of Dalfopristin caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [19]
Pexidartinib DMS2J0Z Major Decreased metabolism of Dalfopristin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [22]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Dalfopristin caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
HKI-272 DM6QOVN Major Decreased metabolism of Dalfopristin caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
LY2835219 DM93VBZ Moderate Decreased metabolism of Dalfopristin caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Palbociclib DMD7L94 Moderate Decreased metabolism of Dalfopristin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Dalfopristin caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Bosutinib DMTI8YE Major Decreased metabolism of Dalfopristin caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [27]
Macitentan DMP79A1 Moderate Decreased metabolism of Dalfopristin caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [28]
PF-04449913 DMSB068 Moderate Decreased metabolism of Dalfopristin caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [29]
Indacaterol DMQJHR7 Minor Decreased metabolism of Dalfopristin caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [30]
Ulipristal DMBNI20 Minor Decreased metabolism of Dalfopristin caused by Ulipristal mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [19]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Dalfopristin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [31]
Ivacaftor DMZC1HS Major Decreased metabolism of Dalfopristin caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [19]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Dalfopristin caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [27]
OPC-34712 DMHG57U Major Decreased metabolism of Dalfopristin caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [32]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Dalfopristin caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [33]
Ospemifene DMC4GEI Moderate Decreased metabolism of Dalfopristin caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [34]
Stiripentol DMMSDOY Moderate Decreased metabolism of Dalfopristin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Cannabidiol DM0659E Minor Decreased metabolism of Dalfopristin caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [19]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Dalfopristin caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [35]
Tazemetostat DMWP1BH Major Decreased metabolism of Dalfopristin caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [36]
Mirabegron DMS1GYT Minor Decreased metabolism of Dalfopristin caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [37]
Ripretinib DM958QB Moderate Decreased metabolism of Dalfopristin caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [27]
Avapritinib DMK2GZX Major Decreased metabolism of Dalfopristin caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [19]
Daclatasvir DMSFK9V Moderate Decreased metabolism of Dalfopristin caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [27]
MK-1439 DM215WE Minor Decreased metabolism of Dalfopristin caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [38]
Dolutegravir DMCZGRE Minor Decreased metabolism of Dalfopristin caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [39]
Etravirine DMGV8QU Moderate Decreased metabolism of Dalfopristin caused by Etravirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [40]
Rilpivirine DMJ0QOW Moderate Decreased metabolism of Dalfopristin caused by Rilpivirine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [27]
Maraviroc DMTL94F Moderate Decreased metabolism of Dalfopristin caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [41]
BMS-201038 DMQTAGO Major Decreased metabolism of Dalfopristin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [27]
Aliskiren DM1BV7W Moderate Decreased metabolism of Dalfopristin caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [17]
Levamlodipine DM92S6N Moderate Decreased metabolism of Dalfopristin caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [17]
Tolvaptan DMIWFRL Moderate Decreased metabolism of Dalfopristin caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [42]
Suvorexant DM0E6S3 Major Decreased metabolism of Dalfopristin caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [43]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Dalfopristin caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [44]
ITI-007 DMUQ1DO Major Decreased metabolism of Dalfopristin caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [45]
Naloxegol DML0B41 Major Decreased metabolism of Dalfopristin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [19]
Pemigatinib DM819JF Major Decreased metabolism of Dalfopristin caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [46]
Crizotinib DM4F29C Moderate Decreased metabolism of Dalfopristin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [47]
Brigatinib DM7W94S Major Decreased metabolism of Dalfopristin caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [27]
Ceritinib DMB920Z Moderate Decreased metabolism of Dalfopristin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [48]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Dalfopristin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [49]
Osimertinib DMRJLAT Moderate Decreased metabolism of Dalfopristin caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [31]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Dalfopristin caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [50]
Capmatinib DMYCXKL Moderate Decreased metabolism of Dalfopristin caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Selpercatinib DMZR15V Major Decreased metabolism of Dalfopristin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [20]
Idelalisib DM602WT Moderate Decreased metabolism of Dalfopristin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [52]
GDC-0199 DMH0QKA Major Decreased metabolism of Dalfopristin caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [27]
IPI-145 DMWA24P Moderate Decreased metabolism of Dalfopristin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [53]
Acalabrutinib DM7GCVW Major Decreased metabolism of Dalfopristin caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [54]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Dalfopristin caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [19]
Ponatinib DMYGJQO Moderate Decreased metabolism of Dalfopristin caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [55]
Selumetinib DMC7W6R Major Decreased metabolism of Dalfopristin caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [56]
LGX818 DMNQXV8 Major Decreased metabolism of Dalfopristin caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [57]
Rimegepant DMHOAUG Moderate Decreased metabolism of Dalfopristin caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [58]
Flibanserin DM70DTN Major Decreased metabolism of Dalfopristin caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [59]
Panobinostat DM58WKG Moderate Decreased metabolism of Dalfopristin caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [60]
Siponimod DM2R86O Major Decreased metabolism of Dalfopristin caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [27]
Deflazacort DMV0RNS Major Decreased metabolism of Dalfopristin caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [19]
Fedratinib DM4ZBK6 Minor Decreased metabolism of Dalfopristin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [61]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Dalfopristin caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Entrectinib DMMPTLH Major Decreased metabolism of Dalfopristin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [19]
S-297995 DM26IH8 Moderate Decreased metabolism of Dalfopristin caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [19]
Olaparib DM8QB1D Major Decreased metabolism of Dalfopristin caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [27]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Dalfopristin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [62]
Istradefylline DM20VSK Moderate Decreased metabolism of Dalfopristin caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [20]
Pimavanserin DMR7IVC Moderate Decreased metabolism of Dalfopristin caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [31]
Lefamulin DME6G97 Moderate Decreased metabolism of Dalfopristin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [63]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Dalfopristin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [64]
Enzalutamide DMGL19D Moderate Decreased metabolism of Dalfopristin caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [65]
Darolutamide DMV7YFT Minor Decreased metabolism of Dalfopristin caused by Darolutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [66]
Silodosin DMJSBT6 Moderate Decreased metabolism of Dalfopristin caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [67]
Axitinib DMGVH6N Moderate Decreased metabolism of Dalfopristin caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [19]
Temsirolimus DMS104F Moderate Decreased metabolism of Dalfopristin caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [68]
Upadacitinib DM32B5U Moderate Decreased metabolism of Dalfopristin caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [69]
Tofacitinib DMBS370 Moderate Decreased metabolism of Dalfopristin caused by Tofacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [27]
Avanafil DM75CXN Major Decreased metabolism of Dalfopristin caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [70]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Dalfopristin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [17]
LDE225 DMM9F25 Major Decreased metabolism of Dalfopristin caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [71]
Larotrectinib DM26CQR Moderate Decreased metabolism of Dalfopristin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Dalfopristin caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [19]
Armodafinil DMGB035 Minor Decreased metabolism of Dalfopristin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Dalfopristin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [72]
Apixaban DM89JLN Moderate Decreased metabolism of Dalfopristin caused by Apixaban mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [19]
Brilinta DMBR01X Moderate Decreased metabolism of Dalfopristin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [19]
Cabozantinib DMIYDT4 Moderate Decreased metabolism of Dalfopristin caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [73]
Saxagliptin DMGXENV Moderate Decreased metabolism of Dalfopristin caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [19]
Elagolix DMB2C0E Moderate Decreased metabolism of Dalfopristin caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [74]
Fluticasone DMGCSVF Moderate Decreased metabolism of Dalfopristin caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [27]
⏷ Show the Full List of 97 DDI Information of This Drug

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 The streptogramin antibiotics: update on their mechanism of action. Expert Opin Investig Drugs. 1998 Apr;7(4):591-9.
7 A synthetic alanyl-initiator tRNA with initiator tRNA properties as determined by fluorescence measurements: comparison to a synthetic alanyl-elongator tRNA. Nucleic Acids Res. 1991 Oct 25;19(20):5749-54.
8 An examination of the differential sensitivity to ketolide antibiotics in ermB strains of Streptococcus pyogenes and Streptococcus pneumoniae. Curr Microbiol. 2004 Oct;49(4):239-47.
9 Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001 Oct 25;413(6858):814-21.
10 Review of macrolides and ketolides: focus on respiratory tract infections. Drugs. 2001;61(4):443-98.
11 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
12 Depression of colony formation by human thymus-derived lymphocytes with rifampin and other antimicrobial agents. J Infect Dis. 1981 Jun;143(6):832-5.
13 Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007 Sep;51(9):3385-7.
14 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
15 The protein synthesis inhibitors, oxazolidinones and chloramphenicol, cause extensive translational inaccuracy in vivo. J Mol Biol. 2002 Sep 13;322(2):273-9.
16 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
17 Canadian Pharmacists Association.
18 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
21 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
22 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
24 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
25 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
26 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
27 Cerner Multum, Inc. "Australian Product Information.".
28 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
29 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
30 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
31 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
32 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
33 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
34 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
35 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
36 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
37 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
38 Product Information. Pifeltro (doravirine). Merck &amp Company Inc, Whitehouse Station, NJ.
39 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
40 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
41 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
42 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
43 Product Information. Belsomra (suvorexant). Merck &amp Company Inc, Whitehouse Station, NJ.
44 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
45 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
46 Product Information. Pemazyre (pemigatinib). Incyte Corporation, Wilmington, DE.
47 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
48 Product Information. Zykadia (ceritinib). Novartis Pharmaceuticals, East Hanover, NJ.
49 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
50 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
51 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
52 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
53 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
54 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
55 Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
56 Multum Information Services, Inc. Expert Review Panel.
57 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
58 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
59 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
60 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
61 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
62 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
63 Product Information. Mavyret (glecaprevir-pibrentasvir). Abbott Pharmaceutical, Abbott Park, IL.
64 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
65 Product Information. Xtandi (enzalutamide). Astellas Pharma US, Inc, Deerfield, IL.
66 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
67 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
68 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
69 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
70 Product Information. Cialis (tadalafil). Lilly, Eli and Company, Indianapolis, IN.
71 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
72 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
73 Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
74 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.